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Introduction
The mediastinum is an extrapleural space between the
two pleural cavities. Anatomically the mediastinum is di-
vided into the anterior – prevascular, middle – vascular and
posterior – paravertebral sulcus – costovertebral space 
1. The
mediastinal space is divided into the four parts, according to
clinical-radiological aspect of localization of the pathological
lesions with respect to diagnostic and therapeutical ap-
proach 
2 (Figure 1): 1) Superior mediastinum – retrosternal
thyroid, aortic aneurysm, thymic tumor; 2) Anterior medias-
tinum – thymic tumors, lymphomas, teratomas, pleuroperi-
cardial cysts, dermoid cysts, thymic cysts; 3) Middle medi-
astinum – lymphonodular masses, bronchogenic cysts,
granulomatous diseases (tuberculosis, sarcoidosis), meta-
static carcinoma, pleuropericardial cysts, tumors of the heart,
lymphangiomas, neuroenteric cysts and gastroenteric cysts,
cysts of ductus thoracicus and other rare cysts;  4) Posterior
mediastinum – neurogenic tumors, aortic aneurysms, bron-
chogenic and enterogenic cysts, lymphatic lesions, fibromas,
lipomas and liposarcomas.
Mediastinal lesions are rare and account for 1% of all
tumors. They appear in all age groups, having the highest in-
cidence in the third and fourth decade of life, and they have
even sex distribution. Approximately 60% of lesions are be-
nign, while approximately 40% are malignant in their nature.
Diagnostic methods in mediastinal tumors
When a tumor mass is evident in the mediastinum, there
are a number of both noninvasive and invasive methods for
establishing adequate diagnosis 
3−5.
Noninvasive diagnostic methods in mediastinal tumors:
radiological – standard and profile radiography and tomog-
raphy; esophagography, radioisotope imaging, angiological
methods, computerized tomography (CT) of the thorax,
magnetic resonance (MR) and positron emission tomography
(PET); ultrasonography (ECHO) – transesophageal ECHO
cardiography, ECHO of the heart and large blood vessels,
ECHO of the neck (cervical blood vessels, thyroid gland),
abdominal ECHO; mediastinal tumor markers; cytological
and bacteriological sputum analyses; standard laboratory
tests.
Invasive diagnostic methods in mediastinal tumors: en-
doscopic – bronchoscopy, esophagoscopy, surgical endo-
scopic methods with biopsy – anterior and parasternal medi-
astinoscopy, video-assisted thoracoscopic surgery, VATS
anterior video-mediastinoscopy, puncture needle biopsies –
Aorta
Heart
Fig. 1 – Clinical − radiological division of the mediastinum
1 − Superior mediastinum; 2 − Anterior mediastinum;
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transthoracic, transbronchial, surgical biopsies – parasternal
mediastinotomy and cervical lymph node biopsy, exploratory
thoracotomy and sternotomy – posterolateral or medial ster-
notomy
Careful clinical examination and recognition of signs
and symptoms that may be a part of clinical manifestations
of the mediastinal process (syndrome of compression of the
superior  vena cava, cervical adenopathy, neurological
events, atrophy of the arm muscles, eyelid ptosis, anisocoria,
dysphagia, dyspnea, stridor, etc.) is important for planning of
a diagnostic procedure. A large proportion of mediastinal
tumors and masses − 40% produce no symptoms and are
found incidentally during chest radiograph or imaging stud-
ies of the thorax performed for other reasons, while 97% can
be detected on  postero-anterior (PA) and lateral chest radio-
graphs 
1, 6. The most common symptoms appearing in ap-
proximately one half of all patients are caused by compres-
sion of the surrounding structures by the tumors, dislocation,
occlusion and fixation of the vital structures. Thoracic pain is
a frequent symptom, while the majority of the patients com-
plain of the respiratory disorders (cough and dyspnea) caused
by extramural compression or invasion of the airway
walls.  Other frequent symptoms include dysphagia (due to
esophageal dislocation), syndrome of the superior vena cava
obstruction, pleural pain and pain in the shoulder, paralysis
of the recurrent laryngeal nerve and Horner syndrome,
phrenic nerve paralysis, onset of pleural effusion, back pain,
paraplegia, etc. 
7, 8.
Clinical charachteristics of mediastinal tumors
Mediastinal lymphomas develop as primary neoplasms
of the mediastinal and thymic lymph nodes or they affect
these organs in the course of systemic dissemination of the
lymphoma originating from other sites in the organism 
1.
These are most frequently primary mediastinal tumors, most
of them being localized in the anterior mediastinum, al-
though they may also appear as a mass in the middle medi-
astinum. Mediastinal lymphomas may develop in all age
groups; however they are most common in the third and
fourth decades of life. According to the World Health Or-
ganization (WHO) classification, all lymphoma subtypes
may develop in the mediastinum. The most common is clas-
sical Hodgkin’s lymphoma (cHL) of the nodular sclerosis
type 
9. Non-Hodgkin’s lymphomas (NHL) are less frequent,
with diffuse large B-cell lymphoma (DBCL), primary medi-
astinal B-cell lymphoma with sclerosis (PMBL) and T- lym-
phoblast lymphoma being the most common. Symptoms of
the mediastinal lymphoma are similar to those evidenced in
other mediastinal tumors but, as opposed to other tumors,
lymphomas are accompanied by numerous systemic com-
plaints such as weakness, malaise, fever, elevated body tem-
perature, loss of weight and enhanced overnight sweating.
The above-described diagnostic methods are applied in diag-
nosis of the mediastinal lymphoma. Determination of tumor
mass size, i.e, its bulkiness, expressed as thoracomediastinal
index (TM) is of particular importance for staging of the dis-
ease in these patients 
10. The presence of the mediastinal
adenopathy greater than 1/3 of the horizontal TM (33% of
the thoracic aperture) and/or presence of the nodal mass of
maximal dimension greater than 7 cm indicate a bulky tumor
mass. Rather large bulky tumor mass occupies more than
45% of the thoracic aperture 
11 (Figure 2).
Fig. 2 −  Radiographic verification of bulky mediastinal
lymphoma
As for pulmonary parenchyma infiltration in de novo
Hodgkin’s lymphoma (HL), the pulmonary parenchyma is
almost never affected without affection of the mediastinal
lymph nodes and, almost always, the ipsilateral hilar lymph
nodes 
6, 12. The situation is different in NHL, where pulmo-
nary lesions may also be the only manifestation of intratho-
racic disease in the absence of lymphadenopathy of the upper
mediastinum or hilar lymphadenopathy 
12.
Computerized tomography does not distinguish benign
from the malignant lesions. However, application of intrave-
nous contrast enables differentiation between vascular and
other pathological changes and determination of the relation
of a lesion to the surrounding blood vessels. Computerized
tomography visualizes infiltration of the subpectoral region
and axillae, which do not necessarily need to be palpable
(which is important for planning of the therapy) 
3.
The differential diagnosis of mediastinal tumors
Hodgkin lymphoma, nodular sclerosis subtype
Hodgkin lymphoma, nodular sclerosis is the most
common primary malignant mediastinal neoplasm. As is the
case with PMBL, it is most commonly diagnosed in young
women in the third and fourth decades of life 
13. It is local-
ized in the superior mediastinum spreading to the cervical
lymph nodes, or it may ingrow into the surrounding intratho-
racic organs. More than 90% of mediastinal HL belong to the
nodular sclerosis subtype. Histologically, there is a charac-
teristic nodular growth pattern with wide bands of the hya-
linized, hypocellular connective tissue which surrounds tu-
mor nodules. The tumor tissue is made of a variable number
(usually <  5% tumor mass) of neoplastic, mononuclear
Hodgkin cells, polynuclear Reed-Sternberg (RS) cells and
characteristic lacunar cells. The classical immunophenotype
is CD45-, CD20-, EMA-, CD30+, CD15+, LMP+ 
14, 15. AtVolumen 65, Broj 2 VOJNOSANITETSKI PREGLED Strana 169
Mihaljević B, et al. Vojnosanit Pregl 2008; 65(2): 167–170.
presentation, the bulky form of the disease is found in 40%
of all patients and the disease is manifested by numerous
systemic complaints. Planning of suitable therapy is based on
the international prognostic score (IPS), which considers the
following prognostic parameters as unfavorable: male sex,
age above 45, hypoalbuminemia (less than 4 g/dL), anemia
(Hb below 10.5 g/dL), leukocytosis above 16 000, lympho-
cytopenia (600/mm3 or 8%) and clinical stage IV 
16, 17.
Primary mediastinal B-cell lymphoma with sclerosis
Primary mediastinal B lymphoma with sclerosis
(PMBL) is a subtype of the DBCL, which is, based on its
frequency, the second most frequent mediastinal neo-
plasm 
18, 19. The tumor is frequent in women in the third and
fourth decades of their life, while it is rare in men in the fifth
decade 
20, 21. It is a special type of the diffuse large cell NHL
originating from the thymic B-lymphocytes and it is charac-
terized by particular clinical, immunophenotypic and genetic
properties 
22, 23. From both histological and prognostic points
of view, 3 subgroups of DBCL may be distinguished (origi-
nating from the germinal center, activated B-cells and
PMBL) 
13. Histologically, PMBL is characterized by diffuse
proliferation of the large lymphoid cells accompanied by
prominent sclerosis; tumor cells are large with prominently
pale cytoplasm with multinuclear cells being also occasion-
ally present which makes the differential diagnosis between
HL impossible in the absence of detailed immunohisto-
chemical tests 
24. Immunophenotypically, they are charac-
terized by positivity for CD45, CD20, CD79α however also
by negativity for CD3, CD5, CD10, CD21 and HLA DR
I/II 
25. The tumor cells express B-cell antigens; however, as
opposed to other large cell lymphomas originating from B-
lymphocytes, they do not express HLA antigens and immu-
noglobulins 
26. In the majority of patients, the tumor is mani-
fested as a large intrathoracic mass located in the anterior
mediastinum. Symptoms include dyspnea, cough, superior
vena cava syndrome, pleural and/or pericardial effusion 
20, 21.
In most patients evidence of the disease is limited to the
chest. However, in 25% of patients dissemination occurs in
the course of diseases progress, usually to the extranodal lo-
cations, such as kidneys, adrenal glands, liver, skin, brain
and digestive tract. Prognosis is less favorable in patients
with the affected intrathoracic organs in comparison with
those in whom the disease is localized only within the medi-
astinum. Where there is involvement of the extrathoracic or-
gans, particularly sub diaphragmatic ones, prognosis is par-
ticularly poor 
18, 20.
Precursor T-cell lymphoblast lymphoma/leukemia
Precursor T-cell lymphoblast lymphoma/leukemia is a
neoplasm originating from the lymphoblasts determined for T-
cell differentiation and it involves bone marrow, blood and it is
occasionally primarily manifested as lymph node tumor or it
may be located extranodally. As opposed to acute lymphoblast
leukemia, since they biologically represent the same entity, di-
agnosis of precursor T-lymphoblast lymphoma is usually
made in patients having large nodal/extranodal tumor mass
and less than 25% of the lymphoblasts in the bone marrow.
Precursor T-cell lymphoblast lymphoma accounts for ap-
proximately 85−90% of all lymphoblast lymphomas 
14, 15. The
disease is most frequently evidenced in men in the second and
third decades of their life 
27. The tumor is manifested in 50%
of the patients as a fast-growing, large mediastinal mass which
is frequently accompanied by the development of pleural
and/or pericardial effusions. High leukocytosis with true pic-
ture of leukemia is present in individual cases. In addition to
the mediastinal and bone marrow changes, peripheral lymph-
adenopathy or skin, liver, spleen Waldeyer ring, central nerv-
ous system and gonadal involvement may be present as well.
Microscopically, the tumor is composed of moderately-sized
cells with sparse cytoplasm, round or notched nuclei and in-
distinct nucleolus. The mitotic index is high with frequent
“starry sky” effect. Differentiation from other mediastinal
lymphomas is based on immunohistochemical analyses. All
cases are TdT and CD3. Most cases also express CD1a, CD2,
CD7 and CD43, while staining for CD4 and CD8 is vari-
able 
14, 15.
Conclusion
It is important to emphasize the accurate diagnosis of
mediastinal lymphomas, by adequate patohistological and
immunohistochemical analysis which can provide appropri-
ate therapy.
REFERENCES
1.  Bartlett NL, Wagner ND. Lymphoma of the mediastinum. In:
Pearson FG, Cooper JD, Deslauriers J, Ginsberg RJ, Hiebert CA,
Patterson G, et al, editors. Thoracic surgery. Section VII. Medi-
astinum. 2nd ed. New York: Churchill Livingstone; 2002. p.
1724−31.
2.  Skarin AT. Atlas of Diagnostic Oncology. 2nd ed. London:
Mosby-Year Book Europe; 1996.
3.  Castellino RA, Hilton S, O'Brien JP, Portlock CS. Non-Hodgkin
lymphoma: contribution of chest CT in the initial staging
evaluation. Radiology 1996; 199(1): 129−32.
4.  Carlsen SE, Bergin CJ, Hoppe RT. MR imaging to detect chest
wall and pleural involvement in patients with lymphoma: effect
on radiation therapy planning. AJR Am J Roentgenol 1993;
160(6): 1191−5.
5.  Tesoro-Tess JD, Balzarini L, Ceglia E, Petrillo R, Santoro A,
Musumeci R. Magnetic resonance imaging in the initial staging
of Hodgkin's disease and non-Hodgkin lymphoma. Eur J Ra-
diol 1991; 12(2): 81−90.
6.  Yoneda KY, Morissey BM, Shelton DK. Mediastinal tumors − a di-
agnostic approach business briefing: US Respiratory Care.
Available from:
 http://  www.touchrespiratorydisease.com/mediastinal-
tumors-diagnostic-approach-a766-1.html
7.  Mihaljević B, Sretenović M, Jancić-Nedeljkov R, Petrović M. Acute
megakaryoblastic leukaemia with mediastinal tumor. Haema-
tologia (Budap) 1996; 27(3): 155−8.
8.  Mihaljević B, Nedeljkov-Janćić R, Cemerikić-Martinović V, Babić D,
Colović M. Ki-67 proliferative marker in lymph node aspiratesStrana 170 VOJNOSANITETSKI PREGLED Volumen 65, Broj 2
Mihaljević B, et al. Vojnosanit Pregl 2008; 65(2): 167–170.
of patients with non-Hodgkin's lymphoma. Med Oncol 2006;
23(1): 83−89.
9.  Jaffe ES, Muller-Hermelink K. Hodgkin's Disease. In: Mauch PM,
Armitage JO, Diehl V, Hoppe RT, Weiss LM, editors. Hodgkin's
disease. Philadhelphia: Lippincot Williams & Wilkens; 1999. p.
181.
10. Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ.
Brief chemotherapy, Stanford V, and adjuvant radiotherapy for
bulky or advanced-stage Hodgkin's disease: a preliminary re-
port. J Clin Oncol 1995; 13(5): 1080−8.
11. Glimelius I, Molin D, Amini RM, Gustavsson A, Glimelius B, En-
blad G. Bulky disease is the most important prognostic factor
in Hodgkin lymphoma stage IIB. Eur J Haematol 2003; 71(5):
327−33.
12. Mentzer SJ, Reilly JJ, Skarin AT, Sugarbaker DJ. Patterns of lung
involvement by malignant lymphoma. Surgery 1993; 113(5):
507−14.
13. Staudt LM, Dave S. The biology of human lymphoid malignan-
cies revealed by gene expression profiling. Adv Immunol 2005;
87: 163−208.
14. Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and ge-
netics. Tumours of haematopetic and lymphoid tissues. World
Health Organization Classification of Tumours. Lyon: IARC
Press; 2001.
15. Gatter K, Delsol G. Hodgkin’s Lymphoma. In: Gatter K, Delsol G,
editors. Atlas: the diagnosis of lymphoproliferative diseases.
Oxford: Oxford University Press Inc; 2002. p. 59−63.
16. Hasenclever D, Diehl V. A prognostic score for advanced Hodg-
kin's disease. International Prognostic Factors Project on Ad-
vanced Hodgkin's Disease. N Engl J Med 1998; 339(21):
1506−14.
17. Jaković LR, Mihaljević BS, Jovanović MD, Bogdanović AD, Marti-
nović VM, Kravić TK, et al. The expression of Ki-67 and Bcl-2
in Hodgkin's lymphoma: correlation with the International
Prognostic Score and bulky disease: a study by the Serbian
Lymphoma Study Group (SLG). Med Oncol 2007; 24(1):
45−53.
18. Menestrina F, Chilosi M, Bonetti F, Lestani M, Scarpa A, Novelli P,
et al. Mediastinal large-cell lymphoma of B-type, with sclerosis:
histopathological and immunohistochemical study of eight
cases. Histopathology 1986; 10(6): 589−600.
19. Lichtenstein AK, Levine A, Taylor CR, Boswell W, Rossman S, Fein-
stein DI, et al. Primary mediastinal lymphoma in adults. Am J
Med 1980; 68(4): 509−14.
20. Kirn D, Mauch P, Shaffer K, Pinkus G, Shipp MA, Kaplan WD, et
al. Large-cell and immunoblastic lymphoma of the mediasti-
num: prognostic features and treatment outcome in 57 pa-
tients. J Clin Oncol 1993; 11(7): 1336−43.
21. Lazzarino M, Orlandi E, Paulli M, Sträter J, Klersy C, Gianelli U, et
al. Treatment outcome and prognostic factors for primary me-
diastinal (thymic) B-cell lymphoma: a multicenter study of 106
patients. J Clin Oncol 1997; 15(4): 1646−53.
22. Addis BJ, Isaacson PG. Large cell lymphoma of the mediasti-
num: a B-cell tumour of probable thymic origin. Histopathol-
ogy 1986; 10(4): 379−90.
23. Isaacson PG, Norton AJ, Addis BJ. The human thymus contains
a novel population of B lymphocytes. Lancet 1987; 2(8574):
1488−91.
24. van Besien K, Kelta M, Bahaguna P. Primary mediastinal B-cell
lymphoma: a review of pathology and management. J Clin
Oncol 2001; 19(6): 1855−64.
25. Tsang P, Cesarman E, Chadburn A, Liu YF, Knowles DM. Mo-
lecular characterization of primary mediastinal B cell lym-
phoma. Am J Pathol 1996; 148(6): 2017−25.
26. Pileri SA, Gaidano G, Zinzani PL, Falini B, Gaulard P, Zucca E, et
al. Primary mediastinal B-cell lymphoma: high frequency of
BCL-6 mutations and consistent expression of the transcrip-
tion factors OCT-2, BOB.1, and PU.1 in the absence of im-
munoglobulins. Am J Pathol 2003; 162(1): 243−53.
27. Warnke RA, Weiss LM, Chan JKC, Cleary ML, Dorfman RF.
Tumors of the lymph nodes and spleen. Washington: Armed
Forces Institute of Pathology; 1994.
The paper was received on August 1, 2007. 